ArticleFrontiers in ophthalmology2026
Cataract surgery outcomes in pseudoexfoliation syndrome: a large multicenter database study.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate intraoperative and postoperative complications and visual acuity (VA) outcomes of cataract surgery in pseudoexfoliation (PEX) eyes compared to non-PEX eyes. Methods: We included eyes undergoing phacoemulsification across eight centers in the United Kingdom between July 2003 and March 2015. We categorized these into four groups based on the presence of PEX and other ocular comorbidities. Complications and VA were calculated among each group. Multivariable adjusted models were used to obtain adjusted differences in VA outcomes and adjusted relative risks (RR) of complications. Results: 172,008 eyes were included. PEX was present in 1.2% of the study population. PEX eyes had more posterior capsular rupture, zonular dialysis, nucleus drop, and conversion to extracapsular extraction (adjusted RR = 2.3 [95% CI = 1.7 - 3.0], 6.7 [4.9 - 9.0], 2.5 [1.2 - 5.4], and 2.6 [1.03 - 6.3], respectively). Postoperatively, PEX eyes experienced more intraocular pressure ≥ 22 mmHg and IOL dislocation requiring surgical intervention (adjusted RR = 1.6 [1.1 - 2.3] and 7.3 [4.4 - 12.2], respectively). After accounting for the effect of ocular copathology, PEX eyes had similar postoperative VA outcomes (adjusted RR of achieving LogMAR <= 0.3 = 0.99, 95% CI = 0.95 - 1.02) and VA gain ≥ 0.3 logMAR (adjusted RR = 1.05, 95% CI = 0.99 - 1.11) at 4-12 weeks, compared to non-PEX eyes. Conclusions: Cataract surgery in PEX has more intraoperative complications, but the visual outcomes were favorable. These findings can inform clinical decision-making and patient counseling in managing cataracts in individuals with PEX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.